WO2011088429A1 - Hydrolyzed lecithins - Google Patents

Hydrolyzed lecithins Download PDF

Info

Publication number
WO2011088429A1
WO2011088429A1 PCT/US2011/021455 US2011021455W WO2011088429A1 WO 2011088429 A1 WO2011088429 A1 WO 2011088429A1 US 2011021455 W US2011021455 W US 2011021455W WO 2011088429 A1 WO2011088429 A1 WO 2011088429A1
Authority
WO
WIPO (PCT)
Prior art keywords
lysophospholipids
phospholipids
mixture
animal feed
animal
Prior art date
Application number
PCT/US2011/021455
Other languages
French (fr)
Inventor
Stefaan Van Dyck
Bart Vennekens
Bruno Coppens
Filip Nuyens
Original Assignee
Kemin Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemin Industries, Inc. filed Critical Kemin Industries, Inc.
Priority to CN201180005913.7A priority Critical patent/CN102906271B/en
Priority to EP11733508.3A priority patent/EP2524050A4/en
Priority to BR112012017276A priority patent/BR112012017276A2/en
Publication of WO2011088429A1 publication Critical patent/WO2011088429A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23JPROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00Phosphatide compositions for foodstuffs, e.g. lecithin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/158Fatty acids; Fats; Products containing oils or fats
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/70Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75Feeding-stuffs specially adapted for particular animals for birds for poultry

Definitions

  • the present invention relates generally to feed and food ingredients and, more specifically, to a composition of hydrolyzed lecithins that have markedly improved functionality.
  • lecithins are incorporated at levels ranging from 0.1 to 3% and acts to increase the digestibility of fats and their transport out of the liver.
  • lecithins are modified by enzymatic hydrolysis to change their functionality.
  • Lysolecithins which are structurally related to lecithins can also be used to improve animal performance. Lysolecithins differ from lecithins in the way they exhibit emulsification. Lecithin has a low HLB -value (hydrophilic/lipophilic balance) which promotes oil in water emulsification. Alternatively lysolecithins have a higher HLB value which promotes oil in water emulsification. In the context of nutrient digestion this is an important element as lipids will be emulsified better in the intestinal tract which promotes absorption.
  • HLB -value hydrophilic/lipophilic balance
  • Lysolecithins in particular lysophosphatidylcholine (LPC) are involved in a variety of important biological processes.
  • Lysophosphatidylcholine is the mono-acyl derivative of phosphatidylcholine (PC) and can be produced by the action of phospholipases.
  • the PC molecule is re-formed by the action of acyl transferase enzymes re-combining the fatty acid chain to the sn-2 position. The cleavage and reformation of this ester bond rather than de novo synthesis is the driver for the exchange dynamic of LPC in living cell membranes.
  • Lysophospholipids are known to be involved in regulation of guanylate and adenylate cyclase activity; chemotaxis of human monocytes; chemotaxis of mouse thymus lymphoma cells; activation of human T-lymphocytes and the impairment of endothelium-derived relaxing factor-mediated arterial vasodilation.
  • Lysophospholids have important and varied roles within biological systems that are precisely dependent on the quantities of lysophospholipids available to the cell, and on the negative feedback processes, which further regulate these concentrations.
  • the present invention includes a new hydrolyzed lecithin composition that provides unexpectedly strong additional benefits to the existing products known in the agricultural and food industry. A number of functionalities are discussed using the new and specific composition of phospholipids and lysophospholipids.
  • the formulation provides enhanced functionality when compared with other formulations that are commercially available and/or described in the art.
  • the formulation can be obtained in several ways. It can be formulated by combining lecithins and lysolecithins that are commercially available. Alternatively it can be formulated from the pure chemical compounds that are obtained from organic synthesis or industrial separation of these compounds in lecithin. Another method is to hydrolyze lecithins or lysolecithins using known methods of enzymatic hydrolysis.
  • the formulation is characterized by: (a) The relatively low level of phosphorous containing lipids of between about 16% and 32% and preferably approximately 21-24%; (b) the high ratio of lysophospholipids to other phospholipids of between about 1.4: 1 and 1:0.6 and preferably approximately 1/1; and (c) the preferred ratios between the four main
  • the formulation provides lysophosphatidylcholine in a molar amount between about 27.71 + 6, lysophosphatidylinositol in a molar amount between about 15.82 + 5, lysophosphatidylethanilamine in a molar amount between about 13.65 + 3, lysophosphatidic acid in a molar amount between about 6.98 + 3, and other phospholipids in a molar amount between about 35.84 + 10.7 and all values inside such ranges.
  • the identification of all phospholipids and their ratios can be obtained from mainly two analytical techniques.
  • the first one is 31 P-NMR. Different phospholipids can be identified from the chemical shift in the NMR spectrum. Quantification is possible via integration of the signals.
  • Another valuable technique is HPLC.
  • An HPLC system can be used to separate the different components of the phospholipid formulation.
  • a universal detector such as an electron light scattering detector can be used to quantify the concentration of all compounds.
  • the formulation has the composition specified in Table 1.
  • Table 1 Composition of the phospholipid moiety of a typical formulation expressed as weight percentage and as relative molar composition
  • compositions of lecithin depending on the source can be formulated from these natural products, the ranges for variation for the disclosed formulation are set out in Table 2, which also sets out a similar analysis for two commercial products used for comparison in the examples.
  • the formulation is characterized by: (a) The relatively low level of phosphorous containing lipids of between about 16% and 32% and preferably approximately 24%; (b) the high ratio of lysophospholipids to other phospholipids of between about 1.4: 1 and 1:0.61 and preferably approximately 1/1; and (c) the specific preferred ratio's between the 4 main lysophospholipids, LPC, LPI, LPE and LPA, as shown in Table 3. Table 3 - Prefered ratios of the components in the lysophospholipid fraction and the total lecithin fraction.
  • the preferred ratio of lysophospholipids to phospholipids in the formulation is 1 + 0.2 / 1.
  • Phospholipids and lysophospholipids can have several types of fatty acid chains in the sn-l and sn-2 position. Phospholipids have two fatty acid chains, whereas lysophospholipids have only one fatty acid chain. The chain length and even more the number of unsaturated bonds in the fatty acid substituents have an important effect on the molecular structure and hence the physicochemical and/or biological properties of the phospholipid or lysophospholipid.
  • the composition of the fatty acid substituents in phospholipids and lysophospholipids can be determined by high performance liquid chromatography combined with triple quadrapole linear ion trap mass spectrometry by a person skilled in the art.
  • the lysophospholipid mixture from current invention is characterized by very high proportions of unsaturated fatty acid substituents in LPC, LPE and LPI compared to the respective lysophospholipids in typical soy lecithin (Table 4).
  • the absolute levels of saturated fatty acid substituents in native lysophospholipids from soy lecithin remain remarkably constant after hydrolysis, but the weight percentage of
  • polyunsaturated fatty acid substituents is increased several-fold.
  • the ratio of polyunsaturated fatty acids to saturated fatty acids for all lysophospholipid fractions was at least 5.
  • the level and type of fatty acid substituents in the phospholipids is not relevant, as the remaining
  • phospholipids in the hydrolyzed lecithin have essentially the same molecular structure and hence physicochemical properties as in the native lecithin.
  • Any person skilled in the art could propose an analogous rationale based on molecular fractions instead of weight percentages, but would achieve similar conclusions, because the molecular weights of saturated and unsaturated fatty acids are almost equal and the amount of CI 8 fatty acid is highly exceeding the fraction of C16 fatty acids.
  • Hydrolyzed lecithin also known as lysolecithins, is typically dosed between 25g and lOOOg per metric ton of feed. In a preferred embodiment between 50 and 250 gram is dosed per metric ton of feed.
  • Lysolecithins can be dosed as such by spraying the product on feed.
  • Liquid carriers can be used to dilute the product in order to promote the homogenous distribution in the feed.
  • a dry product can be obtained by mixing the lysolecithin formulation with suitable carriers such as silica gel, limestone, vegetable fibers, salts, bentonite and the like.
  • suitable carriers such as silica gel, limestone, vegetable fibers, salts, bentonite and the like.
  • An antioxidant can be added to protect the lipids against oxidation due to the increased surface of dry products.
  • a total of 84 one-day old male Ross 308 broiler chickens were used in a digestibility trial that was conducted, and consisted of a 7-day period of adaptation to the respective experimental diets starting at the age of 14 days followed by a 4-day main balance period (21 - 25 days of age) with ad libitum feeding and total excreta collection. From day 1 to 14, the birds were housed on deep litter under conventional conditions for lighting, heating and ventilation. From day 14 to 24, the birds were housed in individual balance cages, consisting of a wire floor (a plastic tray for total excreta collection placed under the floor), and drinking cup and feed trough in front. Feed and drinking water were provided ad libitum.
  • the animals were subjected to the usual health and vaccination program.
  • the animals were subjected to a 23 L/ ID light schedule.
  • Treatment effects were compared using the analysis of variance and treatment means were separated using the least significant difference. The computation was done using the SAS ® program version 9.1 (Statistical Analysis System Institute, Cary, NC).
  • T-0 Besides a control group (T-0) in which the space in the formulations was replaced with 500g of the carrier, there were five treatments.
  • T- 1 and T-2 other commercially available lysolecithins have been included in the diet.
  • Treatment 3 is based on the disclosed formulation, T-4 includes a synthetic emulsifier, ethoxylated ricinoleate, and T-5 is a combination of the synthetic emulsifier with lysolecithins.
  • lysophospholipid mixture The product was added to the feed as a premixture, which is further indicated as LB I. This premixture contained 50 % (w/w) Commercial Product 1, 30 % (w/w) silica and 20 % (w/w) limestone. A novel lysophospholipid composition, designated LC liquid,was produced according to the present invention. The product was added to the feed as an alternative, lysophospholipid containing premixture, further indicated asLB II. This alternative premixture contained 25 % (w/w) LC liquid, 30 % (w/w) silica and 45 % (w/w) limestone. The chemical composition of both lysophospholipid sources was determined by 32 P-NMR (Spectral Service, Germany) and is given in Table 9.
  • Lysophosphatidyl choline 515 3.17 10.90 5.27 21.51
  • Antibiotic growth promoters and cocciodio stats were not used in the diets.
  • the final feeds were manufactured in horizontal mixers with a capacity of 0.60 tonne with precision 1: 10 000.
  • Basal diets for the three experimental periods were prepared by single mixing.
  • excreta collection period started and finished with 12h starvation. Also during this period feed intake and will be strictly recorded and birds weighted at beginning and ending of the period. The excreta collection was performed two 2 times per day and samples were be immediately frozen for posterior analysis.
  • Table 10 Composition of the standard (T0-T3) and reformulated (T4-T5) basal diets and calculated nutritional values (starter 0-1 Id, grower 12-21d, finisher 22-28d) T0-T3 T4-T5
  • Threonine % 0.17 0.17 0.15 0.17 0.17 0.15
  • Vitamins and minerals 1 % 1 1 1 1 1 1 1 1
  • vit. A 10.000 UI
  • vit. D3 2.800 UI
  • vit. E 36 mg
  • LB I Commercial Product 1
  • LC liquid are both lysophospholipid sources, but differ from each other in several parameters.
  • LPC, LPI and LPA concentrations are significantly higher in LC liquid, while the level of LPE is comparable in both products.
  • the level of total phospholipids is significantly higher in Commercial Product 1, due to the presence of unhydrolyzed phospholipids such as PC, PI, PE and PA. Since the lysophospholipid forms are the active compounds, the inclusion rate of the test products was based on lysophospholipid contents.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)

Abstract

A specific lecithin composition comprising phospholipids and lysophospholipids is described that can be used as an animal feed additive for the improvement of digestibility parameters and consequently gut health and animal performance. In addition, the mixture possesses useful biological and chemical properties that can be utilized in the animal feed and human food industries. The composition is chemically characterized by means of HPLC-ELSD, HPLC-MS/MS and 31P-NMR and its biological functionalities are fully described.

Description

HYDROLYZED LECITHINS
Background of the Invention
[0001] This application claims priority to United States Patent Application Serial No.
61/295,431, filed January 15, 2010, and incorporates the same herein in its entirety by this reference.
[0002] The present invention relates generally to feed and food ingredients and, more specifically, to a composition of hydrolyzed lecithins that have markedly improved functionality.
[0003] Attempts to improve animal performance have followed a variety of strategies, including efforts to improve digestion and absorption of nutrients. For this purpose, several feed additives based on emulsifiers have been marketed all over the world. There are broadly two categories of products. The first makes use of synthetic emulsifiers, such as ethoxylated ricinoleates, polysorbates, and sorbitan esters. Another class of emulsifiers is natural products such as lecithins. Soybean lecithin is widely used as an additive for animal diets. It is
incorporated at levels ranging from 0.1 to 3% and acts to increase the digestibility of fats and their transport out of the liver. In some cases the lecithins are modified by enzymatic hydrolysis to change their functionality.
[0004] Lysolecithins, which are structurally related to lecithins can also be used to improve animal performance. Lysolecithins differ from lecithins in the way they exhibit emulsification. Lecithin has a low HLB -value (hydrophilic/lipophilic balance) which promotes oil in water emulsification. Alternatively lysolecithins have a higher HLB value which promotes oil in water emulsification. In the context of nutrient digestion this is an important element as lipids will be emulsified better in the intestinal tract which promotes absorption.
[0005] Lysolecithins, in particular lysophosphatidylcholine (LPC), are involved in a variety of important biological processes. Lysophosphatidylcholine is the mono-acyl derivative of phosphatidylcholine (PC) and can be produced by the action of phospholipases. The PC molecule is re-formed by the action of acyl transferase enzymes re-combining the fatty acid chain to the sn-2 position. The cleavage and reformation of this ester bond rather than de novo synthesis is the driver for the exchange dynamic of LPC in living cell membranes.
[0006] The precise lysophospholipids to be produced by the enzyme are dependent upon the constituents of the lecithin used as the phospholipid source and the conditions for enzymatic hydrolysis. [0007] Lysophospholipids are known to be involved in regulation of guanylate and adenylate cyclase activity; chemotaxis of human monocytes; chemotaxis of mouse thymus lymphoma cells; activation of human T-lymphocytes and the impairment of endothelium-derived relaxing factor-mediated arterial vasodilation. They are also known to modulate smooth muscle contractility; induce changes to the conformation of calmodulin binding protein; modulate protein kinase-C activity; and stimulate guanasine triphosphatase hydrolysis of the pro-oncogene product p21.
[0008] Lysophospholids have important and varied roles within biological systems that are precisely dependent on the quantities of lysophospholipids available to the cell, and on the negative feedback processes, which further regulate these concentrations.
Summary of the Invention
[0009] The present invention includes a new hydrolyzed lecithin composition that provides unexpectedly strong additional benefits to the existing products known in the agricultural and food industry. A number of functionalities are discussed using the new and specific composition of phospholipids and lysophospholipids. The formulation provides enhanced functionality when compared with other formulations that are commercially available and/or described in the art.
[0010] The formulation can be obtained in several ways. It can be formulated by combining lecithins and lysolecithins that are commercially available. Alternatively it can be formulated from the pure chemical compounds that are obtained from organic synthesis or industrial separation of these compounds in lecithin. Another method is to hydrolyze lecithins or lysolecithins using known methods of enzymatic hydrolysis.
[0011] The formulation is characterized by: (a) The relatively low level of phosphorous containing lipids of between about 16% and 32% and preferably approximately 21-24%; (b) the high ratio of lysophospholipids to other phospholipids of between about 1.4: 1 and 1:0.6 and preferably approximately 1/1; and (c) the preferred ratios between the four main
lysophospholipids LPC, LPI, LPE and LPA, of 4.5 + 1 / 2.5 + 0.5 / 2 + 0.5 / 1 + 0.25 and all values inside such ranges. [0012] In a preferred embodiment, the formulation provides lysophosphatidylcholine in a molar amount between about 27.71 + 6, lysophosphatidylinositol in a molar amount between about 15.82 + 5, lysophosphatidylethanilamine in a molar amount between about 13.65 + 3, lysophosphatidic acid in a molar amount between about 6.98 + 3, and other phospholipids in a molar amount between about 35.84 + 10.7 and all values inside such ranges.
Detailed Description of Preferred Embodiments
[0013] The identification of all phospholipids and their ratios can be obtained from mainly two analytical techniques. The first one is 31 P-NMR. Different phospholipids can be identified from the chemical shift in the NMR spectrum. Quantification is possible via integration of the signals. Another valuable technique is HPLC. An HPLC system can be used to separate the different components of the phospholipid formulation. A universal detector such as an electron light scattering detector can be used to quantify the concentration of all compounds.
[0014] In a preferred embodiment the formulation has the composition specified in Table 1.
Table 1 - Composition of the phospholipid moiety of a typical formulation expressed as weight percentage and as relative molar composition
Constituent Composition
% w/w % mol/mol
LPC (lysophosphatidylcholine) 5.02 27.71
LPI (lysophosphatidylinositol) 3.17 15.82
LPE 2.26 13.65
(ly sopho sphatidylethanilamine)
LP A (lysophosphatidic acid) 1.06 6.98
other phospholipids 9_198 35.84
Sum 21.49 100
Phosphorous 1.09
[0015] Variations in the composition of lecithin depending on the source (soybean, sunflower, etc.) or natural variations between different batches of lecithin or lysolecithin from the same natural source can occur. As the compositions of the present invention can be formulated from these natural products, the ranges for variation for the disclosed formulation are set out in Table 2, which also sets out a similar analysis for two commercial products used for comparison in the examples.
Table 2 - Composition of the phospholipid moiety of a typical formulation and concentration ranges for the weight percentage and for the relative molar composition
Product / Constituent Composition
Current Invention % w/w % mol/mol
LPC 5.02 + 1.75 27.71 + 6
LPI 3.17 + 1 15.82 + 5
LPE 2.26 + 0.5 13.65 + 3
LPA 1.06 + 0.5 6.98 + 3
Other phospholipids 9.98 + 3 35.84 + 10.7
Sum 21.49 + 6.2 100 + 27.7
Phosphorous 1.09 + 0.25
Commercial Product 1 % w/w % mol/mol
LPC 3.57 ± 0.40 12.95 + 2.04
LPI 1.08 + 0.55 2.84 + 0.10
LPE 2.48 ± 0.38 9.46 + 1.33
LPA 1.26 + 0.54 6.10 + 1.41
Other phospholipids 29.64 + 1.47 68.66 + 1.29
Sum 38.08 + 1.32 100 + 6.17
Commercial Product 2 % w/w
LPC 3.30 ± 0.25
LPI 1.88 + 0.70
LPE 1.98 + 0.13
LPA 0.75 ± 0.04
[0016] An artisan can predict that specific deviations from the specified ranges could occur due to natural variation of the lecithins and lysolecithins used to formulate the product without eliminating the functionality of the disclosed formulation.
[0017] The formulation is characterized by: (a) The relatively low level of phosphorous containing lipids of between about 16% and 32% and preferably approximately 24%; (b) the high ratio of lysophospholipids to other phospholipids of between about 1.4: 1 and 1:0.61 and preferably approximately 1/1; and (c) the specific preferred ratio's between the 4 main lysophospholipids, LPC, LPI, LPE and LPA, as shown in Table 3. Table 3 - Prefered ratios of the components in the lysophospholipid fraction and the total lecithin fraction.
Lysophospholipids Ratio
LPC/LPI/LPE/LPA 4.5 + 1 / 2.5 + 0.5 / 2 + 0.5 / 1 + 0.25
LPC/LPI 2 + 0.5
LPC/LPE 2 + 0.5
LPC/LPA 4 + 1.5
LPI/LPE 1 + 0.25
LPI/LPA 3 + 0.5
LPE/LPA 2 + 0.5
[0018] The preferred ratio of lysophospholipids to phospholipids in the formulation is 1 + 0.2 / 1.
[0019] Phospholipids and lysophospholipids can have several types of fatty acid chains in the sn-l and sn-2 position. Phospholipids have two fatty acid chains, whereas lysophospholipids have only one fatty acid chain. The chain length and even more the number of unsaturated bonds in the fatty acid substituents have an important effect on the molecular structure and hence the physicochemical and/or biological properties of the phospholipid or lysophospholipid. The composition of the fatty acid substituents in phospholipids and lysophospholipids can be determined by high performance liquid chromatography combined with triple quadrapole linear ion trap mass spectrometry by a person skilled in the art. The lysophospholipid mixture from current invention is characterized by very high proportions of unsaturated fatty acid substituents in LPC, LPE and LPI compared to the respective lysophospholipids in typical soy lecithin (Table 4). The absolute levels of saturated fatty acid substituents in native lysophospholipids from soy lecithin remain remarkably constant after hydrolysis, but the weight percentage of
polyunsaturated fatty acid substituents is increased several-fold. The ratio of polyunsaturated fatty acids to saturated fatty acids for all lysophospholipid fractions was at least 5. The level and type of fatty acid substituents in the phospholipids is not relevant, as the remaining
phospholipids in the hydrolyzed lecithin have essentially the same molecular structure and hence physicochemical properties as in the native lecithin. Any person skilled in the art could propose an analogous rationale based on molecular fractions instead of weight percentages, but would achieve similar conclusions, because the molecular weights of saturated and unsaturated fatty acids are almost equal and the amount of CI 8 fatty acid is highly exceeding the fraction of C16 fatty acids.
Table 4 - Absolute and relative levels of fatty acid substituents (SFA, saturated fatty acids; UFA, unsaturated fatty acids; PUFA, polyunsaturated fatty acids) in lysophospholipids as a weight
Fraction Fatty acid substituents Typical soy Hydrolyzed lecithin of lecithin the current invention
LPC SFA (C16:0 and C18:0), (w/w)% 0.174 0.171
UFA (C16: l and C18: l), (w/w)% 0.157 0.584
PUFA (C18:2 and C18:3), (w/w)% 0.480 1.796
Ratio PUFA:SFA 2.8 10.5
LPE SFA (C16:0 and C18:0), (w/w)% 0.111 0.057
UFA (C16: l and C18: l), (w/w)% 0.070 0.278
PUFA (C18:2 and C18:3), (w/w)% 0.269 1.050
Ratio PUFA:SFA 2.4 18.4
LPI SFA (C16:0 and C18:0), (w/w)% 0.349 0.325
UFA (C16: l and C18: l), (w/w)% 0.081 0.323
PUFA (C18:2 and C18:3), (w/w)% 0.423 2.330
Ratio PUFA:SFA 1.2 7.2
Dosage
[0020] Hydrolyzed lecithin, also known as lysolecithins, is typically dosed between 25g and lOOOg per metric ton of feed. In a preferred embodiment between 50 and 250 gram is dosed per metric ton of feed.
Combination with carriers
[0021] Lysolecithins can be dosed as such by spraying the product on feed. Liquid carriers can be used to dilute the product in order to promote the homogenous distribution in the feed.
[0022] Alternatively a dry product can be obtained by mixing the lysolecithin formulation with suitable carriers such as silica gel, limestone, vegetable fibers, salts, bentonite and the like. An antioxidant can be added to protect the lipids against oxidation due to the increased surface of dry products. Example 1
[0023] The formulation was tested to identify its potential to improve the emulsification and absorption of lipids and consequently the digestibility of the fats in the diet. A metabolic trial with broilers was used for this purpose
Trial set-up
[0024] A total of 84 one-day old male Ross 308 broiler chickens were used in a digestibility trial that was conducted, and consisted of a 7-day period of adaptation to the respective experimental diets starting at the age of 14 days followed by a 4-day main balance period (21 - 25 days of age) with ad libitum feeding and total excreta collection. From day 1 to 14, the birds were housed on deep litter under conventional conditions for lighting, heating and ventilation. From day 14 to 24, the birds were housed in individual balance cages, consisting of a wire floor (a plastic tray for total excreta collection placed under the floor), and drinking cup and feed trough in front. Feed and drinking water were provided ad libitum. On day 14, the birds were weighed individually; birds having relatively high or low body weights were discarded. The birds (at 14 days of age) were assigned randomly to each of the 84 individual digestibility cages (adaptation period). On day 21, an additional selection was carried out in order to reduce the number of cages from 12 to 10 for each treatment. For each treatment (n=7), 10 replicates were used. During the main period (21-25 days of age), the birds were fed ad libitum level, while water was freely available. The balance trial (main period) lasted for eleven days, divided into two periods. Preliminary period to adapt the birds to iron cages (7d) and excreta collection period (4d) which started and finished by 12h starvation. In the proper period, excreta were collected two times per day and immediately frozen. During the excreta collection period, feed intake was strictly recorded. The composition and nutritive value of the examined mixtures are presented in Tables 5 and 6.
Table 5: Composition (%)of the diet (g/kg)
Grower Diet
Components Inclusion rate (g/kg)
Maize 170.00
Wheat 441.60
dl-methionine 2.90
L Lysine HCL 3.70
L Threonine 1.40
Limestone 10.00
Monocalcium phosphate 14.70
Soybean meal 46% 246.00
NaCl 1.40
Na - Bicarbonate 3.30
Rapeseed meal 30.00
Pig fat (lard) 40.00
Soybean oil 20.00
Premix (1%) 10.00
Premix of the test additives 5.00
Table 6 - Nutritive value of the diet (g/kg)
Nutrient content of diets (g-kg-1)
ME (kcal/kg) 3085
N x 6.25 190.81
Lysine 11.96
Methionine 0.57
Ca 12.10
P available 5.30
Na 2.20
fat 79.70
[0025] The animals were subjected to the usual health and vaccination program. The animals were subjected to a 23 L/ ID light schedule.
Analyses and Calculations
[0026] After the balance trial and prior to the analyses, the excreta samples were homogenized using a stomacher homogenizer (Interscience, Paris, France), freeze-dried using a Christ 1825
Medizinische apparatebau 326 (Martin Christ, Osterode, Germany), and ground (0.5 mm screen). Samples of feeds and freeze-dried excreta were analyzed for nitrogen (Kjeldahl method: crude protein = N x 6.25), crude fat and gross energy (GE: adiabatic calorimetry). The digestibility of nutrients was determined by the classical balance method. The quantity of nutrients from the feed was decreased by the amount excreted in feces, and this gave the amount of digested components. The ratio of digested constituents to those intake expressed in percent indicated the level of apparent digestibility coefficients. The AME values were calculated by subtracting the GE (gross energy) intake from the GE excreta and then dividing these values by the GE intake. AMEn was calculated by the following equation:
AMEn = (Feed Gross Energy) - ([fecal + urinary] energy)N> where [fecal + urinary] energy)N = ([fecal + urinary] energy) + 34.36 (N intake - [fecal + urinary ] N) and where 34.36 kJ/kg is the mean gross energy of the nitrogenous execratory products in the bird.
[0027] Treatment effects were compared using the analysis of variance and treatment means were separated using the least significant difference. The computation was done using the SAS® program version 9.1 (Statistical Analysis System Institute, Cary, NC).
Products tested
[0028] All tested formulations, including the blank that served as a negative control, were incorporated in a premix that was dosed at 5 kg per ton of feed. The premix included enzymes, a mycotoxin binder and carrier material (premix base). All tested products were incorporated in the premix at a dosage of 500g. The composition and code of the formulations is shown in Table 7.
Table 7 - Description of the treatments-
Ingredient Code and composition of treatment (%)
T-0 T-l T-2 T-3 T-4 T-5
Commercial Product 1 50 25
Commercial Product 2 50
Disclosed formulation 50
Synthetic emulsifier 50 25
Premix base 100 50 50 50 50 50
[0029] Besides a control group (T-0) in which the space in the formulations was replaced with 500g of the carrier, there were five treatments. [0030] In T- 1 and T-2 other commercially available lysolecithins have been included in the diet. Treatment 3 is based on the disclosed formulation, T-4 includes a synthetic emulsifier, ethoxylated ricinoleate, and T-5 is a combination of the synthetic emulsifier with lysolecithins.
Results
[0031] The results are presented in Table 8.
Table 8 -Nutrient digestibility, Excrements/Feed ratio and AMEn for examined diets for all treatments with the respective Standard Error (SE)
Digestibility
Groups Digestibility Digestibility coefficient AMEn Excrements/Feed coefficient coefficient for crude (kcal/kg) ratio
for dry for crude fat.
matter protein
T-0 71.97a 90.92a 86.34a 3003.6a 0.97a
SE (0.67) (0.22) (1.22) (30.66) (0.03)
T-l 72.98a 91.17ab 88.86abc 3051.5ab 0.85b
SE (0.51) (0.22) (0.64) (20.86) (0.03)
T-2 73.30a 91.49b 88.65abc 3085.5bc 0.89ab
SE (0.50) (0.19) (0.90) (23.28) (0.03)
T-3 75.21b 91.33ab 88.25ab 3178. ld 0.76c
SE (0.68) (0.17) (i.oi) (30.83) (0.02)
T-4 72.58a 91.16ab 89.05bc 3001.9a 0.90ab
SE (0.68) (0.29) (1.10) (30.66) (0.03)
T-5 72.89a 91.54b 89.35bc 3052.2ab 0.87b
SE (0.47) (0.15) (0.84) (20.77) (0.02)
10 - Means in the columns with different letters are significantly different at P<0.05
[0032] For dry mater digestibility, the best results were observed for the group III, which included the disclosed formulation. This group was characterized by statistically significantly higher results in dry mater digestibility in comparison to all other groups (p<0.05). The lowest dry matter digestibility was observed for the control group.
[0033] Statistically significant differences were observed in crude protein digestibility between the groups II (commercial lysolecithin formulation 2) and V (a combination of a commercial lysolecithin and a synthetic emulsifier) (p<0.05). In this experiment, a positive numerical trend for crude protein digestibility was observed in groups I, III, IV. [0034] The improvement of crude fat digestibility was statistically significant compared to the control group for groups IV and V (p>0.05).
[0035] In apparent metabolizable energy corrected to zero-nitrogen retention (AMEn) the lowest performance was observed in groups 0 and IV. The best results with regard to this parameter were observed in groups II and III. This improvement was statistically significant.
[0036] Excrements to feed intake ratio in trial was statistically significantly higher in the control group, showing sub-optimal digestibility. Significant improvements were observed for groups I, III and V.
Conclusion
[0037] In conclusion it can be observed that the disclosed formulation brings about a completely different digestibility profile. Compared to the other lysolecithins in the trial, the digestibility for crude fat was numerically the lowest, while there was a very significant difference for both the digestibility of dry matter and excrements to feed ratio. In total this resulted in a significantly higher AMEn for the disclosed formulation compared to all other treatments.
[0038] These results illustrate the superior improvement of digestibility by the disclosed formulation. Furthermore the mode of action is clearly different as a new digestibility profile is observed compared to other lysolecithins. This mode of action is also unexpected since lysolecithins are known as emulsifiers which promote fat digestion absorption. The disclosed formulation clearly does not show this predicted effect.
Example 2
Materials and Methods
[0039] Experimental products. Two different sources of lysophospholipids were used in the trial. Commercial Product 1 from Example 1 was used as an example of a standard
lysophospholipid mixture. The product was added to the feed as a premixture, which is further indicated as LB I. This premixture contained 50 % (w/w) Commercial Product 1, 30 % (w/w) silica and 20 % (w/w) limestone. A novel lysophospholipid composition, designated LC liquid,was produced according to the present invention. The product was added to the feed as an alternative, lysophospholipid containing premixture, further indicated asLB II. This alternative premixture contained 25 % (w/w) LC liquid, 30 % (w/w) silica and 45 % (w/w) limestone. The chemical composition of both lysophospholipid sources was determined by 32 P-NMR (Spectral Service, Germany) and is given in Table 9.
Table 9. Chemical composition of the lysophospholipid mixtures determined by P-NMR
(Spectral Service, Germany)
Commercial Product 1 LC liquid
MW % w/w mol-% % w/w mol-%
Lysophosphatidyl choline 515 3.17 10.90 5.27 21.51
Lysophosphatidyl inositol (LPI) 570 0.91 2.85 2.10 7.76
Lysophosphatidyl ethanolamine 470 2.85 10.79 2.87 12.86
Lysophosphatidic acid ( LPA) 430 1.55 6.42 1.72 8.43
Other phospholipids 770 30.11 69.04 18.37 49.44
Total phospholipids 38.59 100.00 30.33 100.00
Total phosphorus 1.74 1.47
[0040] Diet formulation. Feed batches were manufactured by grinding maize and wheat using a Skiold disc mill with disc distances set at 1 mm for wheat and maize. The experimental products LB I and LB II were premixed with 10 kg wheat separately for each treatment. The trial was divided in to three feeding periods: starter (0-1 Id), grower (12-20d) and finisher (from 21 to 28 days). The composition of the experimental diets and the calculated value are presented in Table 10. The diets used in the trial were offered in mash form and available ad libitum.
Antibiotic growth promoters and cocciodio stats were not used in the diets. The final feeds were manufactured in horizontal mixers with a capacity of 0.60 tonne with precision 1: 10 000. Basal diets for the three experimental periods were prepared by single mixing.
[0041] Husbandry conditions. The trial was carried out at the POZNAN University of Life Sciences, Department of Animal Nutrition and Feed Management, Poland. The trial facility was located in the station at Gorzyn/Miedzychod, Poland. The housing management, feeding and husbandry conditions used in the POZNAN University facility were regarded as representative for a modern commercial broiler operation in Europe and were similar to those used in Example 1. The trial was carried out with 120 one day old Ross 308 chicken broilers. The total treatment duration was 28 days with a 3 phase feeding system (starter, grower and finisher). The animals were obtained from a breeding farm without disease problems. The birds were weighed and assigned to the dietary treatments in order to achieve maximum possible homogeneity within each group and minimum differences between all trial groups. From 0 to 14 days birds were reared as a group outside metabolic cages. At 14 days birds were randomly allocated to one of 120 cages. Each cage contained one bird. Each cage was allocated to one of the six dietary treatments detailed in Table 11, resulting in 20 cages per treatment comprising 10 cages with female birds and 10 cages of male birds. The balance period for digestibility study
compromising total excreta collection occurred from day 24 to day 28. The excreta collection period started and finished with 12h starvation. Also during this period feed intake and will be strictly recorded and birds weighted at beginning and ending of the period. The excreta collection was performed two 2 times per day and samples were be immediately frozen for posterior analysis.
[0042] Nutritional analysis of the diets. Starter, grower and finisher diets were analyzed according to AOAC methods for dry matter, crude protein, fat and NDF. Gross energy was determined using a bomb calorimeter with benzoic acid as a standard.
[0043] Environment control. Environmental conditions (maximum and minimum temperature) and humidity were recorded daily using electronic equipment. Each room was equipped with two condition recorders allocated on opposite walls. Environmental temperatures in the room were modified during the trial according to the recommendations. The condition of the experimental animals and litter was observed twice per day.
[0044]
[0045] Digestibility and AMEa level measurement. Samples of feeds and freeze-dried excreta were analysed for nitrogen (Kjeldahl method: crude protein = N x 6.25), crude fat and gross energy (GE: adiabatic calorimetry). The digestibility of nutrients was determined by the classical balance method. The quantity of nutrients from the feed was decreased by the amount excreted in faeces, and this gave the amount of digested components. The ratio of digested constituents to the intake expressed as a percentage indicated the level of apparent digestibility coefficients. The AME values were calculated as in Example 1.
[0046] Statistical analysis of data. Statistical differences between experimental diets were evaluated by analysis of variance using the GLM procedure of SAS (SAS Inst. Inc., Cary, NC, U.S.) according following formula:
Yij = μ + ai +E ij where Fy- is the observed dependent variable , , represents the effect of the diet, and £¾· represents the random error. Differences among diet means were determined using a Duncan means comparison when the significance of the model was P < 0.05.
[0047] Table 10. Composition of the standard (T0-T3) and reformulated (T4-T5) basal diets and calculated nutritional values (starter 0-1 Id, grower 12-21d, finisher 22-28d) T0-T3 T4-T5
Starter Grower Finisher Starter Grower Finisher
Maize % 36.52 39.9 46.55 38.28 41.1 47.86
Wheat % 15 15 15 15 15 15
Soybean meal 44% % 38.6 34.5 28.51 38.14 34.2 28.3
Soybean Oil % 5.4 6.7 3.3 4.1 5.8 2.6
Animal fat % - - 3.0 - - 2.6
Lysine % 0.3 0.3 0.18 0.3 0.3 0.18
Methionine % 0.16 0.13 0.1 0.16 0.13 0.1
Threonine % 0.17 0.17 0.15 0.17 0.17 0.15
Limestone % 0.8 0.55 0.46 0.8 0.55 0.46
Monocalcium phosphate % 1.6 1.4 1.3 1.6 1.4 1.3
NaHC03 % 0.1 0.1 0.1 0.1 0.1 0.1
Salt % 0.35 0.35 0.35 0.35 0.35 0.35
Vitamins and minerals1 % 1 1 1 1 1 1
Calculated nutritional values
Crude protein % 23.0 21.5 19.5 22.98 21.49 19.53
Ca % 1.054 0.913 0.846 1.054 0.912 0.843
P, available % 0.508 0.457 0.425 0.508 0.458 0.428
Na % 0.189 0.189 0.187 0.190 0.189 0.188
Total methionine % 0.517 0.46 0.415 0.518 0.46 0.417
Total Lysine % 1.42 1.24 1.09 1.42 1.24 1.09
AMEn MJ/kg 12.7 13.2 13.4 12.4 13.0 13.2 kcal/kg 3035 3155 3203 2964 3107 3155
Each kg of feed contains per label: vit. A: 10.000 UI; vit. D3: 2.800 UI; vit. E: 36 mg; Cu
Table 11. Dietary treatments
Dose of Dose of LPC
Code Dietary treatment ly sopho spholipid in finished feed mixture in finished feed
TO Standard diet - -
Commercial Product 1 3.96 g/mt
Tl Standard diet + LB I 250 g/mt
125 g/mt
Commercial Product 1 7.92 g/mt
T2 Standard diet + LB I 500 g/mt
250 g/mt
T3 Standard diet + LB II 500 g/mt LC liquid 125g/mt 6.59 g/mt
Reformulated diet + LB I 500 Commercial Product 1 7.92 g/mt
T4
g/mt 250 g/mt
Reformulated diet + LB II 500 6.59 g/mt
T5 LC liquid 125g/mt
g/mt
Results
[0048] Nutrient digestibilities and AMEa levels of male birds. Improvements in fat digestibility were observed due to the addition of lysophospholipids. Nitrogen retention was affected both by LB I and LB II (P < 0.05) compared to the standard diet. All experimental groups were characterized by a higher nitrogen retention than the group fed the standard diet (P < 0.50). Better nitrogen retention was also observed for the birds that received the reformulated diets. Use of LB I at 250 g/mt and 500 g/mt and LB II at 500 g/mt significantly improved AMEn compared to the standard diet. Similar responses (P < 0.05) were observed for the reformulated diets.
Table 12. Digestibility of dry mater (DM), organic dry matter (ODM), crude fat (CF\ crude fiber (CFi), neutral detergent fiber (NDF), nitrogen retention (N) and apparent metabolizable energy
(AMEn) by male birds
DM ODM CF CFi NDF N AMEn
Standard diet 69.7 71.5 85.1 27.9 21.2 87.9 b 2988 b
Standard diet + LB I 250 g/mt 71.0 72.9 87.8 29.8 23.5 89.3 a 3128 a
Standard diet + LB I 500 g/mt 72.8 74.6 88.1 33.1 28.4 90.3 a 3158 a
Standard diet + LB II 500 g/mt 72.2 74.1 86.8 29.6 25.4 90.0 a 3176 a
Reformulated diet + LB I 500 g/mt 71.8 73.6 87.0 31.8 25.5 89.6 a 3186 a
Reformulated diet + LB II 500 g/mt 71.9 73.8 86.5 30.6 24.6 90.2 a 3124 a
SEM 0.414 0.403 0.337 0.888 0.952 0.190 18.34
P 0.353 0.298 0.135 0.658 0.400 0.001 0.017
Means in a column which are significantly different a P < 0.05 are indicated by different letters [0049] Nutrient digestibilities and AMEa levels of female birds. Nitrogen retention and AMEn were affected by the additives (P < 0.05). The lowest nitrogen retention was observed in the case of standard diet (P < 0.05). The other experimental groups did not differ significantly from each other. Similarly, AMEn in diets supplemented with lysophospholipids did not differ significantly from each other, but all were significantly higher than the unsupplemented standard diet.
[0050] Diet Formulation and Analysis. The nutritional composition of the experimental diets is given in Table 14. The analyzed values for crude protein were in line with the calculated values given previously in Table 10.
[0051] Health and Condition. The consistency of the feces during whole trial was normal, no sticky droppings or diarrhoea problems were observed. There were no differences between dietary treatments. There was no mortality during this experiment.
Table 13. Digestibility of dry mater (DM), organic dry matter (ODM), crude fat (CF), crude fiber
(CFi), neutral detergent fiber (NDF), nitrogen retention (N) and apparent metabolizable energy
(AMEn) by female birds
DM ODM CF CFi NDF N AMEn
Standard diet 70.0 71.8 85.9 26.3 21.9 87.9 b 2997 b
Standard diet + LB I 250 g/mt 71.9 73.4 87.8 29.9 23.7 89.8 a 3161 a
Standard diet + LB I 500 g/mt 72.0 74.2 88.5 30.9 27.1 89.8 a 3165 a
Standard diet + LB II 500 g/mt 71.9 73.8 88.6 29.2 25.6 89.6 a 3184 a
Reformulated diet + LB I 500 g/mt 71.7 73.8 87.1 31.0 24.3 89.3 a 3193 a
Reformulated diet + LB II 500 g/mt 71.6 73.7 87.5 31.1 25.2 90.3 a 3134 a
SEM 0.450 0.447 0.355 0.776 0.748 0.179 17.38 P 0.802 0.745 0.260 0.459 0.463 0.001 0.008
Means in a column which are significantly different a P < 0.05 are indicated by different letters
Table 14. Nutritional composition of the experimental diets
TO Tl T2 T3 T4 T5
Starter Gross Energy 4274 4298 4304 4369 4280 4298
Dry Matter 89.99 90.15 90.26 90.29 90.16 90.20
Crude Protein 21.88 22.36 22.58 22.81 22.72 22.98
Crude Fat 7.2 7.3 7.8 7.7 6.61 6.38
Crude fibre 3.3 3.27 4.00 4.00 4.12 3.46
NDF 8.01 7.69 8.43 7.87 8.35 8.12
Grower Gross Energy 4443 4441 4456 4425 4433 4401
Dry Matter 90.16 90.25 90.14 90.15 90.02 90.03
Crude Protein 21.36 22.06 21.49 21.79 21.04 21.02
Crude Fat 8.75 8.98 9.09 8.96 8.33 8.54
Crude fibre 3.79 3.86 3.28 3.12 3.44 3.40
NDF 8.28 8.63 8.41 8.26 8.31 8.16
Finisher Gross Energy 4448 4429 4429 4469 4488 4390
Dry Matter 90.53 90.38 90.36 90.53 90.45 90.54
Crude Protein 19.01 18.56 18.63 18.65 18.18 18.19
Crude Fat 9.10 9.11 8.98 8.93 8.18 7.98
Crude fibre 3.54 3.49 3.47 3.02 3.09 3.26
NDF 8.12 8.57 8.87 8.87 8.26 8.08
Discussion
[0052] Commercial Product 1 (LB I) and LC liquid are both lysophospholipid sources, but differ from each other in several parameters. LPC, LPI and LPA concentrations are significantly higher in LC liquid, while the level of LPE is comparable in both products. The level of total phospholipids, however, is significantly higher in Commercial Product 1, due to the presence of unhydrolyzed phospholipids such as PC, PI, PE and PA. Since the lysophospholipid forms are the active compounds, the inclusion rate of the test products was based on lysophospholipid contents.
[0053] Remarkably, all lysophospholipid additions resulted in significant improvements in nitrogen retention both in male and female birds fed the standard finisher feed. The increase in nitrogen retention of 2.1 % (90.0 % minus 87.9 , Table 12) compared to the standard diet by use of LC liquid at 125 g/mt in male broilers is equivalent to 0.688 g nitrogen more retained in the bird per kilogram of feed consumed, assuming a crude protein content of 215 g/kg. This nitrogen saving represents a contribution of 23.9 kJ or 5.7 kcal in the calculation of AMEn. In contrast, the total AMEn gain observed is 188 kcal (3176 kcal minus 2988 kcal, Table 12) for the same treatment. The increase in nitrogen retention is hence only a limited portion of the total AMEn gain observed. An increase of dry matter digestibility with 2.5 % for a feed with a dry matter content of 900 g/kg would represent an AMEn gain of approximately 90 kcal/kg. An increase of fat digestibility with 1.7 % for a feed with a fat content of 75 g/kg would represent an AMEn gain of 18 kcal/kg. The important increase in AMEn by use of lysolecithin is therefore only partially due to the savings in nitrogen efficiency, and for the remainder part due to the combined effect of improvement in several nutrient fractions.
[0054] For the reformulated finisher feed, the calculated energy of the reformulated diet was only 48 kcal lower than the standard diet (Table 9). The observed AMEn gains due to
lysophospholipid inclusion (Tables 12 and 13) was significantly higher than this amount, and consequently resulted in AMEn values that were significantly higher than the standard diet without lysophospholipids. When the apparent energy values of the lysophospholipid sources are calculated based on the AMEn gains observed in the trial (Table 14), the highest values were obtained for both diets and both male and female birds for LC liquid. Since the additional energy gain due to increasing the inclusion Commercial Product 1 (LB I) from 125 to 250 g/mt is limited, the apparent energy value of LC liquid at 62.5 g/mt is expected to be even higher.
Table 15. Apparent energy values of lysophospholipid source
AMEn value (kcal/kg) AMEn value (kcal/kg) in standard diet in reformulated diet
Dietary treatment males females males females
LB I 125 g/mt 1120 1312
LB I 250 g/mt 680 672 984 976
LC liquid 125 g/mt 1504 1496 1472 1480
[0055] The foregoing description and drawings comprise illustrative embodiments of the present inventions. The foregoing embodiments and the methods described herein may vary based on the ability, experience, and preference of those skilled in the art. Merely listing the steps of the method in a certain order does not constitute any limitation on the order of the steps of the method. The foregoing description and drawings merely explain and illustrate the invention, and the invention is not limited thereto, except insofar as the claims are so limited. Those skilled in the art who have the disclosure before them will be able to make modifications and variations therein without departing from the scope of the invention.

Claims

We claim:
1. A mixture of phospholipids and lysophospholipids, comprising a ratio of
lysophospholipids to phospholipids between about 0.6/1 and about 1.4/1.
2. A mixture of phospholipids and lysophospholipids, comprising a level of phosphorus- containing lipids less than32.
3. A mixture of phospholipids and lysophospholipids, comprising a ratio of
lysophosphatidylcholine to lysophosphatidylinositol to lysophosphatidylethanilamine to lysophosphatidic acid of between 4.5 + 1 to 2.5 + 0.5 to 2 + 0.5 to 1 + 0.25.
4. A mixture of phospholipids and lysophospholipids, in which the weight percentage of polyunsaturated fatty acid substituents in lysophosphatidylcholine,
lysophosphatidylethanolamine, and lysophosphatidylinositol, respectively, is at least 5 times higher than the weight percentage of saturated fatty acid substituents.
5. A method of improving the digestibility of dry matter in an animal feed, comprising the steps of:
(a) obtaining a mixture of phospholipids and lysophospholipids, comprising a ratio of lysophospholipids to phospholipids between about 0.6/1 and about 1.4/1; and
(b) combining said mixture of phospholipids and lysophospholipids with an animal feed containing dry matter to obtain an animal feed with improved dry matter digestibility compared to the animal feed without said mixture of phospholipids and lysophospholipids.
6. A method of improving the apparent metabolizable energy corrected to zero-nitrogen retention of an animal feed, comprising the steps of:
(a) obtaining a mixture of phospholipids and lysophospholipids, comprising a ratio of lysophospholipids to phospholipids between about 0.6/1 and about 1.4/1; and (b) combining said mixture of phospholipids and lysophospholipids with an animal feed to obtain an animal feed with improved apparent metabolizable energy corrected to zero-nitrogen retention compared to the animal feed without said mixture of phospholipids and lysophospholipids.
7. A method of reducing the ratio of excrements to feed of an animal fed an animal feed, comprising the steps of:
(a) obtaining a mixture of phospholipids and lysophospholipids, comprising a ratio of lysophospholipids to phospholipids between about 0.6/1 and about 1.4/1;
(b) combining said mixture of phospholipids and lysophospholipids with an animal feed; and
(c) feeding said animal feed to an animal to reduce the ratio of excrements to feed by the animal compared to that of the animal fed the animal feed without said mixture of phospholipids and lysophospholipids.
8. A method of improving the digestibility of dry matter in an animal feed, comprising the steps of:
(a) obtaining a mixture of phospholipids and lysophospholipids, comprising a ratio of lysophosphatidylcholine to lysophosphatidylinositol to
lysophosphatidylethanilamine to lysophosphatidic acid of between 4.5 + 1 to 2.5 + 0.5 to 2 + 0.5 to 1 + 0.25;
(b) combining said mixture of phospholipids and lysophospholipids with an animal feed containing dry matter to obtain an animal feed with improved dry matter digestibility compared to the animal feed without said mixture of phospholipids and lysophospholipids.
9. A method of improving the apparent metabolizable energy corrected to zero-nitrogen retention of an animal feed, comprising the steps of:
(a) obtaining a mixture of phospholipids and lysophospholipids, comprising a ratio of lysophosphatidylcholine to lysophosphatidylinositol to lysophosphatidylethanilamine to lysophosphatidic acid of between 4.5 + 1 to 2.5 + 0.5 to 2 + 0.5 to 1 + 0.25;
(b) combining said mixture of phospholipids and lysophospholipids with an animal feed to obtain an animal feed with improved apparent metabolizable energy corrected to zero-nitrogen retention compared to the animal feed without said mixture of phospholipids and lysophospholipids.
10. A method of reducing the ratio of excrements to feed of an animal fed an animal feed, comprising the steps of:
(a) obtaining a mixture of phospholipids and lysophospholipids, comprising a ratio of lysophosphatidylcholine to lysophosphatidylinositol to
lysophosphatidylethanilamine to lysophosphatidic acid of between 4.5 + 1 to 2.5 + 0.5 to 2 + 0.5 to 1 + 0.25;
(b) combining said mixture of phospholipids and lysophospholipids with an animal feed; and
(c) feeding said animal feed to an animal to reduce the ratio of excrements to feed by the animal compared to that of the animal fed the animal feed without said mixture of phospholipids and lysophospholipids.
PCT/US2011/021455 2010-01-15 2011-01-17 Hydrolyzed lecithins WO2011088429A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201180005913.7A CN102906271B (en) 2010-01-15 2011-01-17 Hydrolyzed lecithin
EP11733508.3A EP2524050A4 (en) 2010-01-15 2011-01-17 Hydrolyzed lecithins
BR112012017276A BR112012017276A2 (en) 2010-01-15 2011-01-17 mixture of phospholipids and lysophospholipids, and methods for improving dry matter digestibility in an animal feed, for improving apparent metabolizable energy, and for reducing the ratio of animal feed excrement

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29543110P 2010-01-15 2010-01-15
US61/295,431 2010-01-15

Publications (1)

Publication Number Publication Date
WO2011088429A1 true WO2011088429A1 (en) 2011-07-21

Family

ID=44277752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/021455 WO2011088429A1 (en) 2010-01-15 2011-01-17 Hydrolyzed lecithins

Country Status (5)

Country Link
US (2) US8603568B2 (en)
EP (1) EP2524050A4 (en)
CN (1) CN102906271B (en)
BR (1) BR112012017276A2 (en)
WO (1) WO2011088429A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2548498C1 (en) * 2014-01-28 2015-04-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ФГБОУ ВПО "КубГТУ") Modified lecithins production method
EP4233552A1 (en) * 2022-02-25 2023-08-30 Oleon N.V. Emulsifier mixture

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8603568B2 (en) * 2010-01-15 2013-12-10 Kemin Industries, Inc. Hydrolyzed lecithin product to improve digestibility
CA2839993A1 (en) * 2011-06-20 2012-12-27 Nestec S.A. Emulsion comprising lyso-phospholipids
CN104170789B (en) * 2014-07-07 2016-05-11 广东温氏食品集团股份有限公司 A kind of method for breeding of Sanhuang broiler
CN104397446A (en) * 2014-12-09 2015-03-11 重庆综艺制药有限公司 Selenium-enriched pollution-free compound premix containing amino acid micro element complex compounds for meat animals
MA45279A (en) * 2016-03-02 2019-01-09 Pathway Intermediates Ltd FEEDS CONTAINING SPECIFIC GLYCOLIPIDS
GB2569073B (en) * 2016-09-16 2022-04-27 Kemin Ind Inc Animal feed supplement
US11497229B2 (en) 2018-08-31 2022-11-15 Kemin Industries, Inc. Technology for water dispersible phospholipids and lysophospholipids
KR102125165B1 (en) * 2019-01-15 2020-06-19 건국대학교 산학협력단 A method for estimating urinaryenergy of swine

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0075463A2 (en) 1981-09-18 1983-03-30 Kyowa Hakko Kogyo Kabushiki Kaisha Emulsifiers comprising lysophosphatidic acid or a salt thereof and processes for making a dough for use in the production of farinaceous products
EP0260572A1 (en) 1986-09-17 1988-03-23 BASF Corporation Coproduction of low molecular weight esters of alkanols
US4976984A (en) * 1989-01-17 1990-12-11 Kao Corporation Edible oil/fat compositions
EP0870840A2 (en) 1997-04-08 1998-10-14 Tsuji Oil Mill Co., Ltd. Process for manufacturing vegetable lysolecithins
US6068997A (en) * 1999-03-01 2000-05-30 Kemin Industries, Inc. Method for the conversion of lecithin into lysolecithin
US6509055B1 (en) 1998-12-18 2003-01-21 Lovesgrove Research Limited Animal feed supplement comprising specific phospholipid compositions
US20050227945A1 (en) * 2004-04-09 2005-10-13 Cargill, Incorporated Enzymatic modification of lecithin
WO2009037398A2 (en) 2007-07-20 2009-03-26 Isl Innovation Sante Lipides Foodstuff composition to improve digestibility of foodstuff lipids
WO2009046988A2 (en) 2007-10-10 2009-04-16 Chr. Hansen A/S Process for producing a water-in-oil emulsion

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB760011A (en) 1953-05-29 1956-10-31 Adolf Rosenberg Improvements in or relating to animal feeds
GB816343A (en) 1955-04-07 1959-07-08 Hedley Thomas & Co Ltd Mixed triglyceride composition
EP0260573A3 (en) * 1986-09-18 1989-03-22 Lucas Meyer GmbH &amp; Co Process for preparing a hydrolysed lecithin, and the use of the hydrolysed lecithin
JPH02273536A (en) * 1989-04-13 1990-11-08 Yakult Honsha Co Ltd Surface active agent and its manufacture
AT397756B (en) 1990-08-10 1994-06-27 Interpremix Futtermittel Und P Feed additive
NO920067L (en) 1991-01-14 1992-07-15 Ajinomoto Kk FORADDITIVE FOR DRUGS
ATE164490T1 (en) * 1991-12-12 1998-04-15 Nestle Sa HEAT-Stable OIL-IN-WATER EMULSION AND METHOD FOR PRODUCING THE SAME
CN2121137U (en) 1992-05-20 1992-11-11 周朝木 Patient's clothes
GB2277862A (en) 1993-05-12 1994-11-16 Nutec Ltd A nutritional composition for oral administration to an animal
DE19529861A1 (en) 1995-08-14 1997-02-20 Berg & Schmidt Gmbh & Co Lipid concentrate used as fodder additive contg. lipid and lecithin
JPH11269056A (en) 1998-03-24 1999-10-05 Kyowa Hakko Kogyo Co Ltd Cosmetic
WO1999049832A1 (en) 1998-03-31 1999-10-07 Shiseido Company, Ltd. Agents promoting laminin production in skin cells
EP1137402A1 (en) 1998-12-08 2001-10-04 Phares Pharmaceutical Research N.V. Phospholipid compositions
GB9828013D0 (en) 1998-12-18 1999-02-10 Lovesgrove Res Ltd Specific phospholipid-lipid mixtures for inclusion in animal feed
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
JP3589904B2 (en) * 1999-06-17 2004-11-17 花王株式会社 Acidic oil-in-water emulsion composition
JP3051744B1 (en) * 1999-09-16 2000-06-12 クノール食品株式会社 Processed egg products and method for producing the same
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
EP1250057B1 (en) 1999-12-30 2005-11-09 Kemin Industries, Inc. Method for improving the activity of enzymes
CN1323536A (en) 2000-05-15 2001-11-28 大连华农集团有限责任公司 Mixed phospholipid feed and its production process
US7713570B2 (en) * 2004-04-14 2010-05-11 Firouz Jahaniaval Process for preparing high liquid oil, no trans, very low saturates, regular margarine with phospholipids
TWI363600B (en) 2004-09-21 2012-05-11 Kao Corp Acidic oil-in-water emulsion composition
US8603568B2 (en) * 2010-01-15 2013-12-10 Kemin Industries, Inc. Hydrolyzed lecithin product to improve digestibility

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0075463A2 (en) 1981-09-18 1983-03-30 Kyowa Hakko Kogyo Kabushiki Kaisha Emulsifiers comprising lysophosphatidic acid or a salt thereof and processes for making a dough for use in the production of farinaceous products
EP0260572A1 (en) 1986-09-17 1988-03-23 BASF Corporation Coproduction of low molecular weight esters of alkanols
US4976984A (en) * 1989-01-17 1990-12-11 Kao Corporation Edible oil/fat compositions
EP0870840A2 (en) 1997-04-08 1998-10-14 Tsuji Oil Mill Co., Ltd. Process for manufacturing vegetable lysolecithins
US6509055B1 (en) 1998-12-18 2003-01-21 Lovesgrove Research Limited Animal feed supplement comprising specific phospholipid compositions
US6068997A (en) * 1999-03-01 2000-05-30 Kemin Industries, Inc. Method for the conversion of lecithin into lysolecithin
US20050227945A1 (en) * 2004-04-09 2005-10-13 Cargill, Incorporated Enzymatic modification of lecithin
WO2009037398A2 (en) 2007-07-20 2009-03-26 Isl Innovation Sante Lipides Foodstuff composition to improve digestibility of foodstuff lipids
US20100196586A1 (en) * 2007-07-20 2010-08-05 Isl-Innovation Sante Lipides Foodstuff composition to improve digestibility of foodstuff lipids
WO2009046988A2 (en) 2007-10-10 2009-04-16 Chr. Hansen A/S Process for producing a water-in-oil emulsion

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SABIHA: "Lysophospholipids and their role in enhancing Digestion and Absorption", AVITECH TECHNICAL BULLETIN, September 2009 (2009-09-01), pages 1 - 6, XP008163751, Retrieved from the Internet <URL:http://www.avitechnutrition.com/pdf/technical-bulletin/2009/J> [retrieved on 20110426] *
See also references of EP2524050A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2548498C1 (en) * 2014-01-28 2015-04-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ФГБОУ ВПО "КубГТУ") Modified lecithins production method
EP4233552A1 (en) * 2022-02-25 2023-08-30 Oleon N.V. Emulsifier mixture
WO2023161377A1 (en) * 2022-02-25 2023-08-31 Oleon Nv Emulsifier mixture

Also Published As

Publication number Publication date
EP2524050A1 (en) 2012-11-21
EP2524050A4 (en) 2017-05-17
CN102906271B (en) 2016-04-06
US8603568B2 (en) 2013-12-10
CN102906271A (en) 2013-01-30
US9173419B2 (en) 2015-11-03
BR112012017276A2 (en) 2015-09-15
US20110177194A1 (en) 2011-07-21
US20140057016A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
US9173419B2 (en) Method of improving animal feeds using hydrolyzed lecithins
Plumstead et al. Interaction of calcium and phytate in broiler diets. 1. Effects on apparent prececal digestibility and retention of phosphorus
Braña et al. Effect of a novel phytase on growth performance, bone ash, and mineral digestibility in nursery and grower-finisher pigs
US20240225052A1 (en) Animal feed supplement
Ceylan et al. High available phosphorus corn and phytase in layer diets
Lamp et al. Inorganic feed phosphate type determines mineral digestibility, broiler performance, and bone mineralization
Senköylü et al. Performance and egg weight of laying hens fed on the diets with various by-product oils from the oilseed extraction refinery
Wendt et al. Investigations on the availability of inorganic phosphate from different sources with growing White Pekin ducks
Um et al. Effects of microbial phytase supplementation to diets with low non-phytate phosphorus levels on the performance and bioavailability of nutrients in laying hens
Kerr et al. Energy and ether extract digestibility of commercially available lipids fed to broilers
Kubiś et al. Microbial Phytase Improves Performance and Bone Traits in Broilers Fed Diets Based on Soybean Meal and White Lupin Meal
Lamp Evaluating inorganic feed phosphate type and further potential of phytase supplementation using a commercial broiler model
Çelebi et al. Effects of Various Fat Sources Added into the Diets of Laying Hens on Calcium and Phosphorus Metabolism
van Krimpen et al. Phytate degradation in broilers
BR112012017276B1 (en) MIXING OF PHOSPHOLIPIDS AND LYSOPHOSPHOLIPIDS, AND METHODS TO IMPROVE DIGESTIBILITY OF DRY MATTERS IN AN ANIMAL FEED, TO IMPROVE APPARENT METABOLIZABLE ENERGY AND TO REDUCE THE REASON FOR ANIMAL FEEDING
Wilks The Comparative Efficacy of Novel Phytase Enzymes in Young Broiler Diets Through the Use of Different Sampling and Statistical Methods
Hampton Determination of Ileal Digestible Phosphorous Values in Various Inorganic Sources Meat and Bone Meal Sources
Rao et al. Relative bio-availability of different phosphorus supplements in broiler and layer chicken diets
Dubey et al. Growth Performance, Nutrient Utilization and Haemato-biochemical Profile in Ven-cobb Broiler Chicken as Influenced by Dietary Supplementation of Crude Soy Lecithin
Bornholt Efficacy of new phytase enzymes for increasing dietary phosphorus utilization by laying hens
Belyea et al. Bioavailability of phosphorus in stabilized and raw rice bran
Schaumburg et al. Further evaluation of a slope-ratio precision-fed rooster assay for relative bioavailable energy values for fats and oils
Li The effects of phytase supplementation on heavy strain broiler breeders
Abudabos Feeding alternative source of fat to broilers
Shirley Evaluation of phytase, vitamin D3 derivatives, and broiler breed differences on nutrient utilization, broiler performance, leg disorders, and the expression of intestinal calbindin-28 kd mRNA and protein

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180005913.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11733508

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 5712/DELNP/2012

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011733508

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012017276

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012017276

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120712